Show simple item record

dc.contributor.advisorBhattacharjee, Sandipan
dc.contributor.authorAbou-Eid, Michelle
dc.date.accessioned2019-10-31T21:16:34Z
dc.date.available2019-10-31T21:16:34Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10150/634948
dc.descriptionClass of 2019 Abstract & Posteren_US
dc.description.abstractSpecific Aims: To examine the patterns and predictors of off-label antipsychotic use among older adults with dementia in the ambulatory care settings in US. Methods: This was a retrospective, cross-sectional study using pooled data from the National Ambulatory Medical Care Survey (NAMCS) (2005-2015). The study sample consisted of ambulatory visits by older adults (age ≥ 65 years) with dementia who were prescribed off-label antipsychotic(s). Dementia was identified by using ICD-9-CM codes of 290.xx, 294.xx, or 331.xx or by examining use of cholinesterase inhibitors or memantine. Antipsychotics are approved for treating individuals with schizophrenia (ICD-9-CM: 2950x–2959x), bipolar disorder (ICD-9-CM: 2960x, 2961x, 2964x–2969x), Tourette syndrome (ICD-9-CM: 307.23), or Huntington’s disease (ICD-9-CM: 333.4). Patients with these co-occurring diseases were excluded from the final study sample. Predictors of off-label antipsychotic use were determined using multivariable logistic regression adjusting for individual-level factors. All analyses were adjusted for the complex survey design of NAMCS to obtain nationally representative estimates. Main Results: Over the 11-year study period, there over 74 million visits by older adults with dementia without conditions approved for treatment with an antipsychotic, among whom 6.2 million (8.37%) visits received an off-label antipsychotic prescription. Factors that were significantly associated with off-label antipsychotic use were age, gender, race/ethnicity, physician specialty, region, number of medications recorded at the sampled visit, and number of past visits. Conclusions: Considering over 8% of older adults with dementia received off-label antipsychotic, appropriate interventions are warranted to minimize off-label antipsychotic use in this vulnerable population.en_US
dc.language.isoen_USen_US
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author.en_US
dc.subjectNeurocognitive Disordersen_US
dc.subjectOlder Adulten_US
dc.subjectOff label antipsychoticen_US
dc.subjectAmbulatory careen_US
dc.subject.meshAntipsychotic Agentsen_US
dc.subject.meshSchizophreniaen_US
dc.subject.meshBipolar Disorderen_US
dc.subject.meshTourette Syndromeen_US
dc.subject.meshHuntington Diseaseen_US
dc.subject.meshAmbulatory Careen_US
dc.subject.meshMemantineen_US
dc.subject.meshCholinesterase Inhibitorsen_US
dc.subject.meshDementiaen_US
dc.titlePatterns and Predictors of Off-Label Antipsychotic Use Among Older Adults with Dementia in Ambulatory Care Settings in the United States (US)en_US
dc.typetexten_US
dc.typeElectronic Reporten_US
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen_US
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en_US
refterms.dateFOA2019-10-31T21:16:34Z


Files in this item

Thumbnail
Name:
Poster Group 1 36x72.pdf
Size:
322.4Kb
Format:
PDF
Description:
Poster

This item appears in the following Collection(s)

Show simple item record